Irinotecan Fresenius Kabi (Irinotecan Hydrochloride Trihydrate)

Irinotecan Hydrochloride Trihydrate is a pro‑drug that is converted in the liver to the active metabolite SN‑38. SN‑38 binds to the DNA‑topoisomerase I enzyme, stabilising the transient DNA break that the enzyme creates during replication. This prevents DNA re‑ligation, leading to accumulation of DNA damage, cell‑cycle arrest and ultimately tumour cell death.

The dosing regimen for Irinotecan is individualized by the treating oncologist based on factors such as the specific cancer type, treatment protocol, patient weight, performance status and organ function. The prescriber determines the appropriate dose, infusion rate and schedule, and may adjust it during therapy according to clinical response and laboratory monitoring.

The safety of Irinotecan during pregnancy and lactation has not been established. It is classified as contraindicated for use in pregnant women because of potential fetal toxicity, and breastfeeding is generally discouraged while receiving treatment, as the drug may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Irinotecan Fresenius Kabi. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Irinotecan and topotecan are both topoisomerase I inhibitors, but Irinotecan is typically used for colorectal and certain other solid tumours, whereas topotecan is more common in small‑cell lung cancer and ovarian cancer. Irinotecan’s pro‑drug conversion to SN‑38 results in a distinct toxicity profile, with higher rates of severe diarrhoea and neutropenia compared with topotecan.

Irinotecan injection should be stored at 2‑8 °C in a refrigerator, protected from light. The solution must not be frozen or shaken. Prior to administration, it may be diluted with the appropriate diluent under aseptic conditions and used within the time frame recommended by the manufacturer.

Irinotecan is given as an intravenous infusion, usually over 30 to 90 minutes depending on the protocol. The drug is supplied as a sterile injection solution that is diluted with a compatible fluid before infusion. Administration is performed in a clinical setting where vital signs and infusion reactions can be monitored.

The most serious adverse events associated with Irinotecan include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhoea (colitis) that can lead to dehydration and electrolyte imbalance, and hypersensitivity reactions such as anaphylaxis. Prompt recognition and supportive care are essential to mitigate these risks.

Irinotecan is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. It should be avoided in individuals with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment without dose adjustment. Caution is also advised for patients with known UGT1A1 deficiency, as they are at higher risk for toxicity.